Advanced search
Publication Cover
Future Virology Volume 3, 2008 - Issue 2
Submit an article Journal homepage
126
Views
0
CrossRef citations to date
0
Altmetric
Review

Innate Immune Signaling Pathways: Lessons from Vaccinia Virus

Tara Hursta School of Biochemistry & Immunology, Trinity College Dublin, Dublin 2, Ireland. [email protected]
&
Andrew G Bowieb School of Biochemistry & Immunology, Trinity College Dublin, Dublin 2, Ireland. [email protected]
Pages 147-156 | Published online: 29 Feb 2008

Bibliography

  • Meylan E , TschoppJ, KarinM: Intracellular pattern recognition receptors in the host response.Nature442(7098) , 39–44 (2006).
  • Mogensen TH , PaludanSR: Reading the viral signature by Toll-like receptors and other pattern recognition receptors.J. Mol. Med.83(3) , 180–192 (2005).
  • Unterholzner L , BowieAG: The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities.Biochem. Pharmacol.75(3) , 589–602 (2007).
  • Meylan E , TschoppJ: Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses.Mol. Cell22(5) , 561–569 (2006).
  • Seet BT , JohnstonJB, BrunettiCR et al.: Poxviruses and immune evasion. Annu. Rev. Immunol.21 , 377–423 (2003).
  • Bowie A , Kiss-TothE, SymonsJA, SmithGL, DowerSK, O‘NeillLA: A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling.Proc. Natl Acad. Sci. USA97(18) , 10162–10167 (2000).
  • Harte MT , HagaIR, MaloneyG et al.: The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med.197(3) , 343–351 (2003).
  • Stack J , HagaIR, SchroderM et al.: Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med.201(6) , 1007–1018 (2005).
  • Kawai T , AkiraS: TLR signaling.Semin. Immunol.19(1) , 24–32 (2007).
  • Kawai T , AkiraS: TLR signaling.Cell Death Differ.13(5) , 816–825 (2006).
  • Bowie AG : Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity.Clin. Exp. Immunol.147(2) , 217–226 (2007).
  • Akira S , UematsuS, TakeuchiO: Pathogen recognition and innate immunity.Cell124(4) , 783–801 (2006).
  • Watters TM , KennyEF, O‘NeillLA: Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins.Immunol. Cell Biol.85(6) , 411–419 (2007).
  • O‘Neill LA , BowieAG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling.Nat. Rev. Immunol.7(5) , 353–364 (2007).
  • Carty M , GoodbodyR, SchroderM, StackJ, MoynaghPN, BowieAG: The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.Nat. Immunol.7(10) , 1074–1081 (2006).
  • Deng L , WangC, SpencerE et al.: Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell103(2) , 351–361 (2000).
  • Adhikari A , XuM, ChenZJ: Ubiquitin-mediated activation of TAK1 and IKK.Oncogene26(22) , 3214–3226 (2007).
  • O‘Neill LA : How Toll-like receptors signal: what we know and what we don‘t know.Curr. Opin. Immunol.18(1) , 3–9 (2006).
  • Sato S , SugiyamaM, YamamotoM et al.: Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κ B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol.171(8) , 4304–4310 (2003).
  • Meylan E , BurnsK, HofmannK et al.: RIP1 is an essential mediator of Toll-like receptor 3-induced NF-κ B activation. Nat. Immunol.5(5) , 503–507 (2004).
  • Jefferies CA , FitzgeraldKA: Interferon gene regulation: not all roads lead to Tolls.Trends Mol. Med.11(9) , 403–411 (2005).
  • Uematsu S , AkiraS: Toll-like receptors and type I interferons.J. Biol. Chem.282(21) , 15319–15323 (2007).
  • Maloney G , SchroderM, BowieAG: Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10.J. Biol. Chem.280(35) , 30838–30844 (2005).
  • Keating SE , MaloneyGM, MoranEM, BowieAG: IRAK-2 participates in multiple Toll-like receptor signaling pathways to NFκB via activation of TRAF6 ubiquitination.J. Biol. Chem.282(46) , 33435–33443 (2007).
  • Blackburn SD , WherryEJ: IL-10, T cell exhaustion and viral persistence.Trends Microbiol.15(4) , 143–146 (2007).
  • Ejrnaes M , FilippiCM, MartinicMM et al.: Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med.203(11) , 2461–2472 (2006).
  • Brooks DG , TrifiloMJ, EdelmannKH, TeytonL, McGavernDB, OldstoneMB: Interleukin-10 determines viral clearance or persistence in vivo.Nat. Med.12(11) , 1301–1309 (2006).
  • van Den Broek M , BachmannMF, KohlerG et al.: IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-γ and nitric oxide synthetase 2. J. Immunol.164(1) , 371–378 (2000).
  • Netea MG , Van der Meer JW, Kullberg BJ: Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol.12(11) , 484–488 (2004).
  • Shisler JL , JinXL: The vaccinia virus K1L gene product inhibits host NF-κB activation by preventing IκBα degradation.J. Virol.78(7) , 3553–3560 (2004).
  • Gedey R , JinXL, HinthongO, ShislerJL: Poxviral regulation of the host NF-κB response: the vaccinia virus M2L protein inhibits induction of NF-κB activation via an ERK2 pathway in virus-infected human embryonic kidney cells.J. Virol.80(17) , 8676–8685 (2006).
  • Bartlett N , SymonsJA, TscharkeDC, SmithGL: The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence.J. Gen. Virol.83(Pt 8) , 1965–1976 (2002).
  • DiPerna G , StackJ, BowieAG et al.: Poxvirus protein N1L targets the I-κB kinase complex, inhibits signaling to NF-κB by the tumor necrosis factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by Toll-like receptors. J. Biol. Chem.279(35) , 36570–36578 (2004).
  • Cooray S , BaharMW, AbresciaNG et al.: Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol.88(Pt 6) , 1656–1666 (2007).
  • Aoyagi M , ZhaiD, JinC et al.: Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci.16(1) , 118–124 (2007).
  • Liu L , XuZ, FuhlbriggeRC, Pena-CruzV, LiebermanJ, KupperTS: Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion.J. Virol.79(12) , 7363–7370 (2005).
  • Howell MD , GalloRL, BoguniewiczM et al.: Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity24(3) , 341–348 (2006).
  • Zasloff M : Antimicrobial peptides of multicellular organisms.Nature415(6870) , 389–395 (2002).
  • Zhu J , MartinezJ, HuangX, YangY: Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β.Blood109(2) , 619–625 (2007).
  • Waibler Z , AnzagheM, LudwigH et al.: Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J. Virol.81(22) , 12102–12110 (2007).
  • Ishii K , CobanC, KatoH et al.: A Toll-like receptor-independent antiviral response induced by double-stranded B-form of DNA. Nat. Immunol.7(1) , 40–48 (2006).
  • Benavente J , Martinez-CostasJ: Avian reovirus: structure and biology.Virus Res.123(2) , 105–119 (2007).
  • Weber F , WagnerV, RasmussenSB, HartmannR, PaludanSR: Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses.J. Virol.80(10) , 5059–5064 (2006).
  • Langland JO , JacobsBL: The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range.Virology299(1) , 133–141 (2002).
  • Romano PR , ZhangF, TanSL et al.: Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol. Cell Biol.18(12) , 7304–7316 (1998).
  • Garcia MA , GuerraS, GilJ, JimenezV, EstebanM: Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L.Oncogene21(55) , 8379–8387 (2002).
  • Haga IR , BowieAG: Evasion of innate immunity by vaccinia virus.Parasitology130(Suppl.) S11–S25 (2005).
  • Langland JO , KashJC, CarterV, ThomasMJ, KatzeMG, JacobsBL: Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins.J. Virol.80(20) , 10083–10095 (2006).
  • Takaoka A , WangZ, ChoiMK et al.: DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature448(7152) , 501–505 (2007).
  • Schramm B , LockerJK: Cytoplasmic organization of POXvirus DNA replication.Traffic6(10) , 839–846 (2005).
  • Jackson SS , IlyinskiiP, PhilipponV et al.: Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. J. Virol.79(10) , 6554–6559 (2005).
  • Staib C , KislingS, ErfleV, SutterG: Inactivation of the viral interleukin 1β receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.J. Gen. Virol.86 , 1997–2006 (2005).
  • Clark RH , KenyonJC, BartlettNW, TscharkeDC, SmithGL: Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.J. Gen. Virol.87 , 29–38 (2006).
  • Lucas A , McFaddenG: Secreted immunomodulatory viral proteins as novel biotherapeutics.J. Immunol.173(8) , 4765–4774 (2004).
  • McCoy SL , KurtzSE, MacarthurCJ, TruneDR, HefeneiderSH: Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation.J. Immunol.174(5) , 3006–3014 (2005).
  • Tsung A , McCoySL, KluneJR, GellerDA, BilliarTR, HefeneiderSH: A novel inhibitory peptide of Toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice.Shock27(4) , 364–369 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.